535 related articles for article (PubMed ID: 28295154)
1. Phenotypical analysis of ectoenzymes CD39/CD73 and adenosine receptor 2A in CD4
Han L; Sugiyama H; Zhang Q; Yan K; Fang X; McCormick TS; Cooper KD; Huang Q
Australas J Dermatol; 2018 Feb; 59(1):e31-e38. PubMed ID: 28295154
[TBL] [Abstract][Full Text] [Related]
2. Target tissue ectoenzyme CD39/CD73-expressing Foxp3+ regulatory T cells in patients with psoriasis.
Zhang HY; Yan KX; Huang Q; Ma Y; Fang X; Han L
Clin Exp Dermatol; 2015 Mar; 40(2):182-91. PubMed ID: 25284153
[TBL] [Abstract][Full Text] [Related]
3. CD39/CD73 and the imbalance of Th17 cells and regulatory T cells in allergic asthma.
Wang LL; Tang HP; Shi GC; Wan HY; Tang W; Hou XX; Pan LN; Shi BY; Tao LQ
Mol Med Rep; 2013 Nov; 8(5):1432-8. PubMed ID: 24065069
[TBL] [Abstract][Full Text] [Related]
4. Adenosine Generated by Regulatory T Cells Induces CD8
Shi L; Feng M; Du S; Wei X; Song H; Yixin X; Song J; Wenxian G
Biomed Res Int; 2019; 2019():4093214. PubMed ID: 31930120
[TBL] [Abstract][Full Text] [Related]
5. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression.
Deaglio S; Dwyer KM; Gao W; Friedman D; Usheva A; Erat A; Chen JF; Enjyoji K; Linden J; Oukka M; Kuchroo VK; Strom TB; Robson SC
J Exp Med; 2007 Jun; 204(6):1257-65. PubMed ID: 17502665
[TBL] [Abstract][Full Text] [Related]
6. Adenosine and the adenosine A2A receptor agonist, CGS21680, upregulate CD39 and CD73 expression through E2F-1 and CREB in regulatory T cells isolated from septic mice.
Bao R; Shui X; Hou J; Li J; Deng X; Zhu X; Yang T
Int J Mol Med; 2016 Sep; 38(3):969-75. PubMed ID: 27430240
[TBL] [Abstract][Full Text] [Related]
7. Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity.
Häusler SF; Montalbán del Barrio I; Strohschein J; Chandran PA; Engel JB; Hönig A; Ossadnik M; Horn E; Fischer B; Krockenberger M; Heuer S; Seida AA; Junker M; Kneitz H; Kloor D; Klotz KN; Dietl J; Wischhusen J
Cancer Immunol Immunother; 2011 Oct; 60(10):1405-18. PubMed ID: 21638125
[TBL] [Abstract][Full Text] [Related]
8. CD39/CD73/A2a Adenosine Metabolic Pathway: Targets for Moxibustion in Treating DSS-Induced Ulcerative Colitis.
Zhu Y; Zhuang Z; Wu Q; Lin S; Zhao N; Zhang Q; Xie L; Yu S
Am J Chin Med; 2021; 49(3):661-676. PubMed ID: 33683190
[TBL] [Abstract][Full Text] [Related]
9. The abnormal function of CD39
Lu Y; Cheng L; Li F; Ji L; Shao X; Wu B; Zhan Y; Liu C; Min Z; Ke Y; Sun L; Chen H; Cheng Y
Ann Hematol; 2019 Aug; 98(8):1845-1854. PubMed ID: 31154474
[TBL] [Abstract][Full Text] [Related]
10. Human CD4+ CD39+ regulatory T cells produce adenosine upon co-expression of surface CD73 or contact with CD73+ exosomes or CD73+ cells.
Schuler PJ; Saze Z; Hong CS; Muller L; Gillespie DG; Cheng D; Harasymczuk M; Mandapathil M; Lang S; Jackson EK; Whiteside TL
Clin Exp Immunol; 2014 Aug; 177(2):531-43. PubMed ID: 24749746
[TBL] [Abstract][Full Text] [Related]
11. Low expression of CD39 on regulatory T cells as a biomarker for resistance to methotrexate therapy in rheumatoid arthritis.
Peres RS; Liew FY; Talbot J; Carregaro V; Oliveira RD; Almeida SL; França RF; Donate PB; Pinto LG; Ferreira FI; Costa DL; Demarque DP; Gouvea DR; Lopes NP; Queiroz RH; Silva JS; Figueiredo F; Alves-Filho JC; Cunha TM; Ferreira SH; Louzada-Junior P; Cunha FQ
Proc Natl Acad Sci U S A; 2015 Feb; 112(8):2509-14. PubMed ID: 25675517
[TBL] [Abstract][Full Text] [Related]
12. Methotrexate restores the function of peripheral blood regulatory T cells in psoriasis vulgaris via the CD73/AMPK/mTOR pathway.
Yan K; Xu W; Huang Y; Zhang Z; Huang Q; Xin KZ; Ma Y; Han L
Br J Dermatol; 2018 Oct; 179(4):896-905. PubMed ID: 29572822
[TBL] [Abstract][Full Text] [Related]
13. Synergy between the ectoenzymes CD39 and CD73 contributes to adenosinergic immunosuppression in human malignant gliomas.
Xu S; Shao QQ; Sun JT; Yang N; Xie Q; Wang DH; Huang QB; Huang B; Wang XY; Li XG; Qu X
Neuro Oncol; 2013 Sep; 15(9):1160-72. PubMed ID: 23737488
[TBL] [Abstract][Full Text] [Related]
14. Autocrine Adenosine Regulates Tumor Polyfunctional CD73
Gourdin N; Bossennec M; Rodriguez C; Vigano S; Machon C; Jandus C; Bauché D; Faget J; Durand I; Chopin N; Tredan O; Marie JC; Dubois B; Guitton J; Romero P; Caux C; Ménétrier-Caux C
Cancer Res; 2018 Jul; 78(13):3604-3618. PubMed ID: 29559470
[TBL] [Abstract][Full Text] [Related]
15. CD39+Foxp3+ regulatory T Cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis.
Fletcher JM; Lonergan R; Costelloe L; Kinsella K; Moran B; O'Farrelly C; Tubridy N; Mills KH
J Immunol; 2009 Dec; 183(11):7602-10. PubMed ID: 19917691
[TBL] [Abstract][Full Text] [Related]
16. [Increased percentage and defective inhibitory function of CD4
Zhang R; Miao J; Zhang K; Zheng Z; Zhu P
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2019 Nov; 35(11):961-966. PubMed ID: 31878990
[TBL] [Abstract][Full Text] [Related]
17. Isolated CD39 expression on CD4+ T cells denotes both regulatory and memory populations.
Zhou Q; Yan J; Putheti P; Wu Y; Sun X; Toxavidis V; Tigges J; Kassam N; Enjyoji K; Robson SC; Strom TB; Gao W
Am J Transplant; 2009 Oct; 9(10):2303-11. PubMed ID: 19656134
[TBL] [Abstract][Full Text] [Related]
18. Expression of CD73 and A2A receptors in cells from subjects with obesity and type 2 diabetes mellitus.
Guzman-Flores JM; Cortez-Espinosa N; Cortés-Garcia JD; Vargas-Morales JM; Cataño-Cañizalez YG; Rodríguez-Rivera JG; Portales-Perez DP
Immunobiology; 2015 Aug; 220(8):976-84. PubMed ID: 25770019
[TBL] [Abstract][Full Text] [Related]
19. Regulatory T cells negatively affect IL-2 production of effector T cells through CD39/adenosine pathway in HIV infection.
Jenabian MA; Seddiki N; Yatim A; Carriere M; Hulin A; Younas M; Ghadimi E; Kök A; Routy JP; Tremblay A; Sévigny J; Lelievre JD; Levy Y
PLoS Pathog; 2013; 9(4):e1003319. PubMed ID: 23658513
[TBL] [Abstract][Full Text] [Related]
20. Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade.
Yang R; Elsaadi S; Misund K; Abdollahi P; Vandsemb EN; Moen SH; Kusnierczyk A; Slupphaug G; Standal T; Waage A; Slørdahl TS; Rø TB; Rustad E; Sundan A; Hay C; Cooper Z; Schuller AG; Woessner R; Borodovsky A; Menu E; Børset M; Sponaas AM
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32409420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
